277 related articles for article (PubMed ID: 17137902)
1. Risk of new-onset uveitis in patients with juvenile idiopathic arthritis treated with anti-TNFalpha agents.
Saurenmann RK; Levin AV; Feldman BM; Laxer RM; Schneider R; Silverman ED
J Pediatr; 2006 Dec; 149(6):833-6. PubMed ID: 17137902
[TBL] [Abstract][Full Text] [Related]
2. Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients.
Gerloni V; Pontikaki I; Gattinara M; Fantini F
Ann Rheum Dis; 2008 Aug; 67(8):1145-52. PubMed ID: 17981916
[TBL] [Abstract][Full Text] [Related]
3. [Side effects of anti-TNFalpha therapy in juvenile idiopathic arthritis].
Pontikaki I; Gerloni V; Gattinara M; Luriati A; Salmaso A; De Marco G; Teruzzi B; Valcamonica E; Fantini F
Reumatismo; 2006; 58(1):31-8. PubMed ID: 16639486
[TBL] [Abstract][Full Text] [Related]
4. Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis.
Saurenmann RK; Levin AV; Rose JB; Parker S; Rabinovitch T; Tyrrell PN; Feldman BM; Laxer RM; Schneider R; Silverman ED
Rheumatology (Oxford); 2006 Aug; 45(8):982-9. PubMed ID: 16461435
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcomes after withdrawal of anti-tumor necrosis factor α therapy in patients with juvenile idiopathic arthritis: a twelve-year experience.
Baszis K; Garbutt J; Toib D; Mao J; King A; White A; French A
Arthritis Rheum; 2011 Oct; 63(10):3163-8. PubMed ID: 21702011
[TBL] [Abstract][Full Text] [Related]
6. [Anti-TNFalpha treatment of juvenile uveitis].
Fledelius HC; Nielsen SM; Nissen KR; Pedersen FK; Zak MS
Ugeskr Laeger; 2007 Apr; 169(14):1309-12. PubMed ID: 17437693
[TBL] [Abstract][Full Text] [Related]
7. A comparison of response criteria to evaluate therapeutic response in patients with juvenile idiopathic arthritis treated with methotrexate and/or anti-tumor necrosis factor alpha agents.
Lurati A; Pontikaki I; Teruzzi B; Desiati F; Gerloni V; Gattinara M; Cimaz R; Fantini F
Arthritis Rheum; 2006 May; 54(5):1602-7. PubMed ID: 16646003
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type.
Quartier P; Taupin P; Bourdeaut F; Lemelle I; Pillet P; Bost M; Sibilia J; Koné-Paut I; Gandon-Laloum S; LeBideau M; Bader-Meunier B; Mouy R; Debré M; Landais P; Prieur AM
Arthritis Rheum; 2003 Apr; 48(4):1093-101. PubMed ID: 12687553
[TBL] [Abstract][Full Text] [Related]
9. [Indications and adverse events with the use of anti-TNFalpha agents in pediatric rheumatology: experience of a single center].
de Oliveira SK; de Almeida RG; Fonseca AR; Rodrigues MC; Sztajnbok F; Diniz C
Acta Reumatol Port; 2007; 32(2):139-50. PubMed ID: 17572652
[TBL] [Abstract][Full Text] [Related]
10. Etanercept and uveitis in patients with juvenile idiopathic arthritis.
Schmeling H; Horneff G
Rheumatology (Oxford); 2005 Aug; 44(8):1008-11. PubMed ID: 15855187
[TBL] [Abstract][Full Text] [Related]
11. Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey.
Foeldvari I; Nielsen S; Kümmerle-Deschner J; Espada G; Horneff G; Bica B; Olivieri AN; Wierk A; Saurenmann RK
J Rheumatol; 2007 May; 34(5):1146-50. PubMed ID: 17343318
[TBL] [Abstract][Full Text] [Related]
12. Risk factors and longterm outcome of juvenile idiopathic arthritis-associated uveitis in Switzerland.
Bolt IB; Cannizzaro E; Seger R; Saurenmann RK
J Rheumatol; 2008 Apr; 35(4):703-6. PubMed ID: 18278829
[TBL] [Abstract][Full Text] [Related]
13. Drug survival of the first and second course of anti-tumour necrosis factor agents in juvenile idiopathic arthritis.
Tynjälä P; Vähäsalo P; Honkanen V; Lahdenne P
Ann Rheum Dis; 2009 Apr; 68(4):552-7. PubMed ID: 18467515
[TBL] [Abstract][Full Text] [Related]
14. A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis.
Smith JA; Thompson DJ; Whitcup SM; Suhler E; Clarke G; Smith S; Robinson M; Kim J; Barron KS
Arthritis Rheum; 2005 Feb; 53(1):18-23. PubMed ID: 15696578
[TBL] [Abstract][Full Text] [Related]
15. Prevalence and outcome of juvenile idiopathic arthritis-associated uveitis and relation to articular disease.
Grassi A; Corona F; Casellato A; Carnelli V; Bardare M
J Rheumatol; 2007 May; 34(5):1139-45. PubMed ID: 17343317
[TBL] [Abstract][Full Text] [Related]
16. Risk factors for development of uveitis differ between girls and boys with juvenile idiopathic arthritis.
Saurenmann RK; Levin AV; Feldman BM; Laxer RM; Schneider R; Silverman ED
Arthritis Rheum; 2010 Jun; 62(6):1824-8. PubMed ID: 20178126
[TBL] [Abstract][Full Text] [Related]
17. Anti-TNF-alpha treatment: a possible promoter in endogenous uveitis? observational report on six patients: occurrence of uveitis following etanercept treatment.
Kakkassery V; Mergler S; Pleyer U
Curr Eye Res; 2010 Aug; 35(8):751-6. PubMed ID: 20673052
[TBL] [Abstract][Full Text] [Related]
18. Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis.
Tynjälä P; Lindahl P; Honkanen V; Lahdenne P; Kotaniemi K
Ann Rheum Dis; 2007 Apr; 66(4):548-50. PubMed ID: 17068061
[TBL] [Abstract][Full Text] [Related]
19. [Inhibitors of tumour necrosis factor-alpha for the treatment of arthritis and uveitis in childhood].
Heiligenhaus A; Horneff G; Greiner K; Mackensen F; Zierhut M; Foeldvari I; Michels H
Klin Monbl Augenheilkd; 2007 Jun; 224(6):526-31. PubMed ID: 17594625
[TBL] [Abstract][Full Text] [Related]
20. Visual outcomes in children with juvenile idiopathic arthritis-associated uveitis.
Kump LI; Castañeda RA; Androudi SN; Reed GF; Foster CS
Ophthalmology; 2006 Oct; 113(10):1874-7. PubMed ID: 16884776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
